Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing FDA warnings, patent cliffs, or controlled-substance quotas in ANI Pharmaceuticals’ disclosures can feel like decoding another language. Each annual report blends clinical trial data, DEA quota details, and manufacturing risk factors that easily surpass 200 pages. If you have ever searched for “ANI Pharmaceuticals insider trading Form 4 transactions” or tried to locate one footnote on steroid revenue, you know the challenge.
Stock Titan turns those challenges into clarity. Our platform delivers AI-powered summaries the moment an ANI Pharmaceuticals quarterly earnings report 10-Q filing or 8-K hits EDGAR, highlighting revenue by therapeutic class, fresh FDA correspondence, and supply-chain updates. Need real-time alerts? We surface ANI Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive buys and sells minutes after they post. From the ANI Pharmaceuticals annual report 10-K simplified to every ANI Pharmaceuticals 8-K material events explained, you receive concise language, key metrics, and cross-linked definitions—no accounting degree required.
Below you will find every filing type—10-K, 10-Q, 8-K, S-8, DEF 14A—each paired with an AI snapshot that answers the questions investors actually ask: cash flows by product line, R&D spend on rare-disease assets, or how “ANI Pharmaceuticals proxy statement executive compensation” aligns with pipeline milestones. Use our tools to:
- Run an “ANI Pharmaceuticals earnings report filing analysis” in seconds
- Track “ANI Pharmaceuticals executive stock transactions Form 4” before market open
- Master “understanding ANI Pharmaceuticals SEC documents with AI” without sifting through PDFs
Whether you are hunting for segment profitability or compliance triggers, Stock Titan delivers ANI Pharmaceuticals SEC filings explained simply—so you focus on decisions, not document digging.
ANI Pharmaceuticals (ANIP) reported an insider transaction on a Form 4. Senior Vice President, General Counsel & Secretary Meredith W. Cook sold 400 shares of common stock on 10/13/2025 at $90.09 per share under a Rule 10b5-1 trading plan adopted on September 17, 2024.
Following the sale, Cook beneficially owns 75,674 shares, held directly. This filing reflects routine insider activity disclosed for transparency.
ANI Pharmaceuticals officer Krista Davis reported a sale of 1,000 shares of ANIP common stock on 09/19/2025 at a price of $98.04 per share. The sale was executed under a Rule 10b5-1 trading plan adopted August 23, 2024. After the transaction, the reporting person beneficially owns 60,186 shares, held directly. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and records the transaction as a routine, preplanned disposition under the company insider trading plan.
Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals (ANIP), reported a tax-withholding disposition tied to the vesting of restricted stock. On 09/12/2025 she disposed of 1,710 shares of common stock at a price of $97.71 per share; following the transaction she beneficially owns 61,186 shares. The filing notes those shares were withheld to satisfy tax obligations related to the vesting of 4,108 previously granted restricted shares.
The Form 4 was signed via attorney-in-fact on 09/15/2025. This is a routine, non-derivative withholding to cover taxes on vested restricted stock rather than an open-market sale or a new transfer of ownership.
Meredith W. Cook, Senior Vice President, General Counsel & Secretary of Ani Pharmaceuticals (ANIP), reported a sale of 400 shares of the company on 09/12/2025 at a price of $98.42 per share. After the transaction she beneficially owned 76,074 shares. The filing states the sale was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on 09/17/2024, indicating the trade followed an automated plan rather than an ad‑hoc decision. The Form 4 was signed by Ms. Cook on 09/15/2025.
Antonio R. Pera, a director of ANI Pharmaceuticals, Inc. (ANIP), reported a sale of 7,292 shares of the company on 09/03/2025 at a price of $94.94 per share. After the transaction, Mr. Pera beneficially owned 22,660 shares. The Form 4 was signed by an attorney-in-fact and filed following the transaction.
Form 144 notice for ANI Pharmaceuticals, Inc. (ANIP) reports a proposed sale of 7,292 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $692,270.40 and stated approximate sale date of 09/03/2025. The filer identifies prior restricted stock acquisitions of 3,000 shares on 04/27/2023 and 4,292 shares on 03/23/2022, both received from the issuer, and discloses a sale during the past three months of 5,421 shares for $486,406.81 on 08/20/2025. The form includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Insider sale disclosed on Form 4 for ANI Pharmaceuticals, Inc. (ANIP). The filing shows that Matthew J. Leonard, reported as a director, sold 2,528 shares of ANIP common stock on 08/25/2025 at a reported price of $90.62 per share. After the sale, Mr. Leonard beneficially owned 6,864 shares, reported as direct ownership. The Form 4 was signed by attorney-in-fact Meredith W. Cook on 08/26/2025. No derivative transactions or additional remarks are included in the filing.
ANI Pharmaceuticals (ANIP) Form 144 notice shows a proposed sale of 2,528 restricted common shares by or for an identified person through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $229,075.98 and an approximate sale date of 08/25/2025. The filing states those shares were acquired as restricted stock from the issuer on 08/21/2025 and paid for on that date. The form also discloses a separate sale by Matthew Leonard of 6,937 common shares on 08/18/2025 with gross proceeds of $611,644.31. The filer certifies they have no undisclosed material adverse information.
FAQ
What is the current stock price of Ani Pharmaceutic (ANIP)?
What is the market cap of Ani Pharmaceutic (ANIP)?
